These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21886036)

  • 1. Recent diabetes issues affecting the primary care clinician.
    Sando KR; Barboza J; Willis C; Taylor J
    South Med J; 2011 Jun; 104(6):456-61. PubMed ID: 21886036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
    McFarland MS; Brock M; Ryals C
    South Med J; 2011 Jun; 104(6):426-39. PubMed ID: 21886033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 7. Choosing among the incretin agents and why it matters.
    Unger J
    J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
    [No Abstract]   [Full Text] [Related]  

  • 8. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin + saxagliptin for type 2 diabetes.
    Scheen AJ
    Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
    Kuritzky L
    Am J Med Sci; 2010 Aug; 340(2):133-43. PubMed ID: 20571352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.
    McFarland MS; Brock M; Ryals C
    South Med J; 2011 Aug; 104(8):612. PubMed ID: 21886074
    [No Abstract]   [Full Text] [Related]  

  • 12. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin physiology and its role in type 2 diabetes mellitus.
    Svec F
    J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Yin and the Yang of CV risks in patients with diabetes.
    Dangi-Garimella S
    Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
    [No Abstract]   [Full Text] [Related]  

  • 19. Saxagliptin efficacy.
    Valiquette G
    Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
    [No Abstract]   [Full Text] [Related]  

  • 20. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.